Has Rohit Bakshi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $196,200 in general payments to Rohit Bakshi, MD across 191 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rohit Bakshi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rohit Bakshi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rohit Bakshi, MD

Neurology · Brookline, MANPI 1598722274

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $145,604 of the $196,200 with a category attached, or 74.2%. EMD Serono, Inc. accounts for 90.5% of it on its own, with 2 other manufacturers making up the rest. Among neurology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$196,200in general payments, 2019–2025

Across 191 payments — averaging $1027.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

EMD Serono, Inc.$178K
Sanofi$15K
E.r. Squibb & Sons, L.L.C.$4K

$1,440,164in research payments, 2019–2025

Across 10 payments — averaging $144,016 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

EMD Serono, Inc.$595K
Bristol Myers Squibb$494K
E.r. Squibb & Sons, L.L.C.$351K

What the payments were for

Consulting fees$19,35010%
Speaking & faculty fees$145,60474%
Travel & lodging$26,46513%
Food & beverage$4,6672%
Education$1130%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
EMD Serono, Inc.	181	$177,587
Sanofi	9	$14,773
E.r. Squibb & Sons, L.L.C.	1	$3,840

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ZEPOSIA$3,840
Mavenclad$526

How this compares

$196,200 in reported general payments places this provider in the 95th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$1,976

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
AubagioTeriflunomide	15	$211,154
VumerityDiroximel Fumarate	16	$134,198
FingolimodFingolimod Hcl	12	$19,006
Teriflunomide	11	$9,117
Baclofen	13	$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
SanofiAubagio	$14,773	$211,15415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 761 neurology providers in Massachusetts.

Other neurology in Brookline

Guy BuckleBrookline$450K
Maria HoutchensBrookline$259K
James StankiewiczBrookline$122K
Christopher WrightBoston$2.5M
Shivang JoshiWestborough$1.2M
Egilius SpieringsWellesley Hills$680K
Thomas ScammellBoston$617K
Salvatore NapoliFoxboro$613K
Alfred SandrockBoston$490K
Joshua KatzWellesley$462K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →